Dr. Tsimberidou on the Personalized Medicine Results

Apostolia Tsimberidou, MD, PhD
Published: Thursday, Jul 21, 2011

Lead author Apostolia M. Tsimberidou, MD, PhD, of the University of Texas MD Anderson Cancer Center, believes that personalized medicine is the future of cancer care and focused on it in a phase I clinical trial conducted at MD Anderson Cancer Center.

The study examined cancer molecular analysis and used matched targeted therapy unique to the aberrations found in the analysis as a way to improve the outcomes of patients. The trial demonstrated that looking at particular genetic abnormalities to select treatment is associated with improved outcomes overall.
Lead author Apostolia M. Tsimberidou, MD, PhD, of the University of Texas MD Anderson Cancer Center, believes that personalized medicine is the future of cancer care and focused on it in a phase I clinical trial conducted at MD Anderson Cancer Center.

The study examined cancer molecular analysis and used matched targeted therapy unique to the aberrations found in the analysis as a way to improve the outcomes of patients. The trial demonstrated that looking at particular genetic abnormalities to select treatment is associated with improved outcomes overall.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x